Statistics for Cost utility analysis of long acting muscarinic antagonists (LAMAs) as an alternative to long acting beta agonists (labas) for treatment of severe COPD in the South African public sector
Total visits
views | |
---|---|
Cost utility analysis of long acting muscarinic antagonists (LAMAs) as an alternative to long acting beta agonists (labas) for treatment of severe COPD in the South African public sector | 18 |
Total visits per month
views | |
---|---|
February 2024 | 3 |
March 2024 | 7 |
April 2024 | 0 |
May 2024 | 0 |
June 2024 | 3 |
July 2024 | 1 |
August 2024 | 4 |
File Visits
views | |
---|---|
MPH_COMH7175A_1946476_03.06.2023.pdf | 48 |
Top country views
views | |
---|---|
South Africa | 17 |
Norway | 1 |
Top city views
views | |
---|---|
Johannesburg | 15 |
Lenasia | 2 |